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Abstract: Rigid control of blood pressure (BP) is essential to prevent cardiovascular disease. 
However, only about 40% of hypertensive patients undergoing pharmacological intervention 
with a single agent achieve their BP goals in contemporary clinical practice. Combined therapy 
using currently available agents is effective in maximizing treatment outcome, although it 
raises medical costs and decreases the drug compliance rate. To overcome such negative 
consequences, a combination tablet containing an angiotensin II receptor blocker (ARB) with 
a small dose of hydrochlorothiazide (HCTZ) is now available on the international market, 
including Japan. This article briefly describes the unique properties of telmisartan, a highly 
selective ARB for the angiotensin II type 1 receptor, including its long-acting characteristics 
and recent prospective multicenter randomized clinical trials, followed by a description of a 
newly-introduced combination tablet in Japan, which contains telmisartan and HCTZ. This article 
also reviews its safety and efficacy based on currently available evidence. Finally, evidence 
comparing telmisartan/HCTZ with other combination therapies is presented.
Keywords: angiotensin II receptor blocker, ARB, blood pressure, hypertension, diuretics, 
PPAR-γ
Introduction
The Japanese Society of Hypertension’s Guidelines for the Management of 
  Hypertension 2009 (JSH 2009)1 recommends rigid control of blood pressure (BP) and 
a target BP level based on a patient’s clinical condition in order to prevent the onset 
of vascular diseases including stroke and myocardial infarction (MI). However, only 
40% of patients with hypertension achieve the target BP goal in contemporary clinical 
practice, indicating the difficulty of BP management with a single hypertensive drug.2 
Therefore, the revised version of JSH 2009 recommends the use of more than one 
antihypertensive drug with a different mechanism of action for patients who fail to 
achieve BP goals with a single agent. Among possible antihypertensive agents, the 
combination of angiotensin II receptor blocker (ARB) with a small dose of diuretic 
not only offers synergistic antihypertensive effects but also provides possible benefits 
other than BP control.
Diuretic agents achieve antihypertensive effects by promoting renal Na+ excretion and 
simultaneously activate the renin-angiotensin system. On the other hand, ARBs inhibit 
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the activated renin-angiotensin system, possibly promoting the 
synergistic antihypertensive effect with the concomitant use 
of an ARB and diuretic agent. Adverse effects on metabolic 
  pathways, such as hypokalemia, decreased carbohydrate 
  tolerance, and hyperuricemia, are a common concern with 
the use of diuretic agents. In contrast, ARBs are known to 
elevate serum K+ levels and improve insulin sensitivity, thereby 
  possibly balancing out the adverse effects of a diuretic agent on 
the metabolic pathway. A small dose of the diuretic agent also 
is considered to be minimized by elevation of uric acid level.
In addition, considering salt-sensitive hypertension 
is essential for hypertension management, a condition 
that is common in Japanese. Administration of ARBs is 
  generally recommended for patients with organ damage. 
The renin-angiotensin system is accelerated with decreasing 
intake of salt, but inhibited when salt intake is increased. 
Hence, limiting the intake of salt should be recommended 
when ARBs are administered for patients with salt-sensitive 
  hypertension, although the concomitant use of a diuretic 
agent is expected to have the same effect as limiting the intake 
of salt by promoting Na+ excretion and possibly enhancing 
the anti-hypertensive effect of ARBs.3
Properties of telmisartan
Angiotensin II type 1 (AT1) receptor blockers, which act 
by selectively blocking the binding of angiotensin II to the 
AT1 receptor, are widely used in current antihypertensive 
therapy.4–6 ARBs are reported to have benefits other than BP 
management and have demonstrated cardiovascular, cerebral, 
and renal protective effects by inhibiting renin-angiotensin 
activation at tissue levels.7–9
Telmisartan is an ARB that is highly selective for the 
AT1 receptor and has a long duration of action due to its 
long terminal elimination half-life.10,11 Its longer half-
life was demonstrated in the MICADO study (Table 1),12 
which evaluated two identically designed multinational, 
  randomized, double-blind, forced-titration studies. A total 
of 930 patients were enrolled in this study. Patients were 
divided either into the telmisartan group (40–80 mg/day) or 
into the valsartan group (80–160 mg/day) and followed up 
for 8 weeks. Uptitration occurred after 2 weeks of low-dose 
treatment. Following 4 weeks of high-dose therapy, patients 
underwent either a 1-day double-blind active treatment or pla-
cebo treatment. After an additional 2-week active treatment, 
a crossover was conducted. The result was very impressive 
in that the last 6-hour mean diastolic BP was decreased by 
7.6 ± 7.9 mmHg in the telmisartan group (n = 447) compared 
with 5.8 ± 7.8 mmHg in the valsartan group (P = 0.0044) 
after active therapy. Similarly, the telmisartan group 
showed reduction in the last 6-hour mean systolic BP of 
11.1 mmHg, whereas it was only 9.1 mmHg in the valsartan 
group (P = 0.0066). After the placebo therapy, the telmisartan 
group (n = 437) showed a reduction in 24-hour mean diastolic 
BP of 7.2 ± 6.5 mmHg compared with 5.5 ± 6.2 mmHg in 
the valsartan group (n = 431) (P = 0.0004). Following the 
placebo therapy, reduction in 24-hour mean systolic BP 
was 10.7 mmHg in the telmisartan group and 8.7 mmHg 
in the valsartan group (P = 0.0024). The mean reductions 
in diastolic and systolic BP were significantly higher in the 
telmisartan group than in the valsartan group. Therefore, it 
was concluded that telmisartan offers more sustained BP 
control because of its long half-life.
Telmisartan is also known to exhibit peroxisome 
  proliferator-activated receptor gamma (PPAR-γ) activa-
tion, and thereby yields a favorable influence on glucose 
and lipid metabolism by improving insulin resistance.13 
Amongst available ARBs in addition to telmisartan, 
  candesartan, irbesartan, and losartan were reported to 
Table 1 Summary of clinical trials investigating efficacy of telmisartan
Names of the clinical trials  
or the authors
Study subjects Main results
MlCADO study12 Hypertensive patients Greater sustained BP reduction than valsartan
Miura et al20 Hypertensive patients  
with type 2 diabetes
Greater improvement of insulin resistance,  
  elevation of adiponectin, and reduction  
in CRP than valsartan or candesartan
ONTARGET study27 Patients at high-risk Equivalent efficacy in preventing  
  cardiovascular events as ramipril
TRANSCEND study28 Patients at high-risk who are  
intolerant to ACE inhibitors
Equivalent efficacy in preventing cardiovascular   
events as placebo 
Tolerance of telmisartan  
in patients intolerant to ACE inhibitors
Abbreviations: BP, blood pressure; CRP, C-reactive protein;   ACE, angiotensin-converting enzyme.Integrated Blood Pressure Control 2010:3 75
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activate PPAR-γ.14–16 However, telmisartan has the strongest 
ability to activate PPAR-γ in vitro compared with other 
ARBs.13 PPAR-γ is an established therapeutic target in the 
  treatment of insulin resistance, diabetes, and the metabolic 
  syndrome.17,18 Telmisartan was also demonstrated to have 
a selective PPAR-γ activation effect and to ameliorate 
insulin resistance.19 In fact, replacement of valsartan and 
  candesartan by telmisartan in hypertensive patients with 
type 2 diabetes demonstrated improvement of insulin 
  resistance, elevation of adiponectin, and reduction in 
high-sensitive C-reactive protein (hs-CRP).20 This study, 
conducted by Miura et al included 18 hypertensive type 2 
diabetes patients aged 36–79 years. These patients were 
treated with valsartan (80 mg/day, n = 11) or candesartan 
(8 mg/day, n = 7) for more than 6 months. During the 
  therapeutic period, clinical and biochemical changes 
were not observed in these patients. The patients then 
received treatment with telmisartan (40 mg/day), instead 
of the previous ARBs, for 12 weeks. Fasting insulin levels 
were significantly decreased after telmisartan treatment 
(10.7 ± 3.8 to 8.6 ± 2.7 mU/L, P  0.01), although 
  reduction in fasting plasma glucose levels (132.5 ± 55.1 
to 126.5 ± 39.3 mg/dL) and glycosylated hemoglobin 
(HbA1c) showed no significant difference (6.89 ± 0.89 to 
6.79 ± 0.96). Significant elevation in serum adiponectin 
levels (6.95 ± 2.91 to 7.97 ± 3.48 µg/mL, P  0.005) and 
a significant reduction in hs-CRP levels (0.154 ± 0.155 to 
0.109 ± 0.120 mg/dL, P  0.05) were observed in these 
patients. Adiponectin and hs-CRP are closely associated 
with insulin resistance and development of atheroscle-
rosis.21,22 Thus, this study suggested that telmisartan has 
beneficial effects on the risk factors for cardiovascular 
disease, which is a major concern in the treatment of type 2 
diabetes. Therefore, it is reasonable to select telmisartan for 
hypertensive patients with metabolic syndrome or insulin 
resistance (Figure 1).
ONTARGET and TRANSCEND 
trials
Angiotensin-converting enzyme (ACE) inhibitors were the 
former standard renin-angiotensin system blockers, proven 
to have benefits other than BP control. Previous randomized 
controlled trials enrolling approximately 150,000 patients 
demonstrated that ACE inhibitors decreased incidences of 
death, myocardial infarction, stroke, and heart failure among 
patients with heart failure.23 They also showed the reduction 
of unfavorable events including left ventricular dysfunction, 
previous vascular disease, and high-risk diabetes.24,25 
Although ACE inhibitors and ARBs have been classified as 
renin-angiotensin system blockers, ARBs have not shown 
their effectiveness on myocardial infarction. Furthermore, 
data from 26 large-scale trials comparing an ACE inhibitor 
against ARB with placebo or another drug class demonstrated 
that ACE inhibitors, but not ARBs, show evidence of blood 
pressure-independent effects on the risk of major coronary 
disease events.26 To evaluate the role of ARBs as an alternative 
or an addition to ACE inhibitors for preventing cardiovascular 
events, a group of investigators evaluated whether the ARB 
telmisartan was inferior to the ACE inhibitor ramipril in a 
study called Ongoing Telmisartan Alone and in Combination 
with Ramipril Global Endpoint Trial (ONTARGET). They 
also investigated whether a combination of the two drugs 
was superior to ramipril alone as a treatment to prevent 
cardiovascular events in high-risk patients who suffered 
from cardiovascular disease or diabetes mellitus but did not 
have heart failure.27 At a median follow-up of 56 months, 
the primary composite outcomes, including death from 
cardiovascular diseases, myocardial infarction, stroke, or 
Effects Renin-angiotensin system↓ PPARγ pathways↑
Hypertension
with insulin resistance
Hypertension
with metabolic syndrome Indications
Telmisartan
Figure 1 Ideal indication of telmisartan.
Abbreviation: PPARγ, peroxisome proliferator activated receptor gamma.Integrated Blood Pressure Control 2010:3 76
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hospitalization for heart failure, was similar in the ramipril 
(16.5%) and telmisartan groups (16.7%). As expected, the 
ramipril group had higher rates of cough (4.2% vs 1.1%, 
P  0.001) and edema (0.3% vs 0.1%, P = 0.01). In the 
  combination group, the primary outcome was seen with 
16.3% showing no significant difference between the two 
drugs. Thus, telmisartan was equally effective as ramipril 
in treating patients with cardiovascular disease or high-risk 
diabetes. Therefore, the ONTARGET study concluded that 
ARBs were not inferior to ACE inhibitors with regard to 
benefit beyond blood pressure control.
A study called Telmisartan Randomised AssessmeNt 
Study in ACE iNtolerant subjects with cardiovascular Disease 
(TRANSCEND) was also performed simultaneously in order 
to evaluate whether telmisartan would be effective for patients 
with cardiovascular disease or diabetes with end-organ 
damage who are intolerant to ACE inhibitors.28 In this study, 
after a 3-week run-in period, 5926 patients were randomly 
assigned to the telmisartan (n = 2954) and placebo groups (n = 
2972). The primary outcome, the composite of cardiovascular 
death, myocardial infarction, stroke, or hospitalization for 
heart failure, occurred in 15.7% of patients in the telmisar-
tan group and 17.0% of the patients in the placebo group, 
  demonstrating no significant difference between these groups 
(P = 0.216). The secondary outcome, the composite of car-
diovascular death, myocardial infarction, or stroke, occurred 
in 13% of patients in the telmisartan group and 14.8% of 
patients in the placebo group (P = 0.048 unadjusted; P = 
0.068 after adjustment for multiplicity of comparisons and 
overlap with primary outcome), indicating a reduction in 
relative risk by 13%.
As mentioned previously, former studies including LIFE,29 
VALUE,30 and CHARM-Alternative31 demonstrated that 
ARBs increased the rates of myocardial infarction compared 
with their opponent drugs. Although no significant difference 
was observed between the losartan and atenolol groups in 
the LIFE study, (9.2% vs 8.7%), higher rates of myocardial 
infarction were observed in those who received the ARB 
treatment (1.07 [0.88–1.31], P = 0.491). In the VALUE 
trial, of the patients assigned to the valsartan base regimen, 
369 patients (4.8%) suffered from myocardial infarction. 
On the other hand, 313 patients (4.1%) suffered from myo-
cardial infarction in the amlodipine base regimen (Hazard 
Ratio 1.19 [1.02–1.38], P = 0.02). The CHARM-Alternative 
trial also demonstrated that an ARB had a higher incidence 
of myocardial infarction. The total number of patients who 
  suffered from myocardial infarction was 75 in the candesartan 
group and 48 in the placebo group (1.52 [1.06–2.18], 
P = 0.025). The results of these studies raised a concern 
that the administration of ARBs possibly increases the rate 
or occurrence of myocardial infarction. The myocardial 
  infarction rate achieved by the TRANSCEND study put 
an end to this concern. The telmisartan group had a lower 
myocardial infarction rate than that in the placebo group, 
despite no significant statistical difference (3.9% vs 5.0%, 
P = 0.059). TRANSCEND is the only study that demonstrated 
the effectiveness of telmisartan in reducing the incidences of 
myocardial infarction. This study therefore helped to identify 
the class effect among the available ARBs.
Characteristics of telmisartan/
HCTZ tablets
Despite the evidence described previously in this paper, 
many patients with hypertension fail to achieve their BP 
goals in contemporary clinical practice, thereby motivating 
  pharmaceutical manufacturers to develop a combination 
tablet. The combination of telmisartan at 40 mg and 
  hydrochlorothiazide (HCTZ) at 12.5 mg (telmisartan 
40 mg/HCTZ 12.5 mg combination tablets) or telmisartan 
80 mg and HCTZ 12.5 mg (telmisartan 80 mg/HCTZ 12.5 mg 
combination tablets) was introduced recently and is now 
available on the international market, including Japan.
Table 2 Summary of clinical trials investigating efficacy of telmisartan/HCTZ tablets
Names of the clinical trial or the authors Study subjects Main results
Higaki32 Hypertensive patients Greater reduction of BP  
than telmisartan alone
Lacourcière et al33 Hypertensive patients Greater reduction of BP  
than telmisartan alone
Neutel et al38 Hypertensive patients Greater reduction of BP  
than losartan/HCTZ tablets
SMOOTH study39 Overweight/obese  
hypertensive patients
Greater reduction of BP  
than valsartan/HCTZ tablets
Abbreviation: BP, blood pressure; HCTZ, hydrochlorothiazide.Integrated Blood Pressure Control 2010:3 77
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As mentioned previously, telmisartan is expected to yield 
a strong and stable antihypertensive effect over a prolonged 
period of time due to strong binding to the AT1 receptor 
and long action. HCTZ is a type of thiazide diuretic, but 
its diuretic effect is weaker than the loop diuretic agent. 
Despite its gradual onset of antihypertensive effect, HCTZ 
has strong and promising effects, especially for patients with 
salt-sensitive hypertension.
Antihypertensive effects  
of telmisartan/HCTZ  
combination tablets
The Japanese phase III clinical trial of the telmisartan 
40 mg/HCTZ 12.5 mg combination tablet was conducted 
on 213 patients with essential hypertension who failed to 
achieve their BP goals (diastolic BP  90 mmHg) with 
40 mg telmisartan. These patients were randomly assigned 
to the study (telmisartan 40 mg/HCTZ 12.5 mg combination 
tablet) and control groups (telmisartan 40 mg). Patients with 
poor compliance were excluded from the study. The primary 
endpoint was trough sitting BP after 8 weeks from the onset 
of the study. At the end of the study period, systolic and 
diastolic BP were decreased by 23.3 mmHg and 14.1 mmHg 
in the study group 2 weeks following the wash-out. After 
randomization, the BP-lowering effect was significantly 
greater in the study group than in the control group (systolic 
BP -14.0 mmHg vs -8.4 mmHg, P = 0.001; diastolic 
BP -9.7 mmHg vs -5.0 mmHg, P  0.0001).32 Given the 
fact that the subjects in this study were poor responders who 
failed to achieve their BP goals with telmisartan at 40 mg, 
  reduction in systolic BP by 23.3 mmHg was significant within 
the current hypertension management (Table 2).
Furthermore, the safety and efficacy of the telmisartan 
80 mg/HCTZ 12.5 mg combination tablet were evaluated 
by Lacourcière et al.33 In this study, the antihypertensive 
effects of a fixed-dose combination of telmisartan 
80 mg/HCTZ 12.5 mg, and telmisartan 80 mg monotherapy 
were compared with patients who had a history of mild 
to moderate essential hypertension and inadequate BP 
  control following 8 weeks of telmisartan monotherapy. At 
the end of this period, 491 patients whose diastolic BP was 
90 mmHg were double-blind randomized to once-daily 
  administration of telmisartan 80 mg/HCTZ 12.5 mg (n = 
246) or telmisartan 80 mg (n = 245). Following 4 and 8 weeks 
of double-blind therapy, trough clinic BP was evaluated. 
At the end of the double-blind treatment, it was found that 
patients who underwent telmisartan 80 mg/HCTZ 12.5 mg 
therapy experienced a further significant decrease in clinic 
  systolic/diastolic BP (-5.7 mmHg) compared with those who 
underwent telmisartan 80 mg monotherapy (-3.1 mmHg) 
(P  0.01). In addition, the number of patients with nor-
malized BP was significantly higher in the telmisartan 
80 mg/HCTZ 12.5 mg group than in the telmisartan 80 mg 
group (41.5% vs 26.1%; P  0.05). The results of this study 
demonstrated that a fixed-dose combination of telmisartan 
80 mg/HCTZ 12.5 mg yields greater reduction in BP in 
nonresponders than for those who continue telmisartan 
monotherapy. Although the difference in the reduction of 
BP was small, it was still considered to be big enough to be 
economically effective, because decreases in systolic BP as 
small as 2 mmHg have a great impact on reducing mortality 
from cardiovascular disease.34
In addition, the dose determination study comparing 
telmisartan 80 mg/HCTZ 12.5 mg vs telmisartan 40 mg/HCTZ 
12.5 mg demonstrated that telmisartan 80 mg/HCTZ 12.5 mg 
was significantly more effective than telmisartan 40 mg/HCTZ 
12.5 mg in reducing mean supine diastolic BP and systolic 
BP (P  0.05 for both).35
In the Japanese dose determination study (phase II), 
responders were defined as patients who achieved their 
systolic BP goals 140 mmHg, or those whose systolic BP 
was less than 10 mmHg. Based on this definition, 87.5% of 
the patients in the telmisartan 40 mg/HCTZ 12.5 mg group 
and 93.7% of the patients in the telmisartan 80 mg/HCTZ 
12.5 mg group achieved their treatment goal.36 Furthermore, 
the Japanese prolonged-administration study for 184 essential 
hypertensive patients who failed to achieve their BP goals 
with telmisartan 40 mg demonstrated a favorable BP control 
with both telmisartan 40 mg/HCTZ 12.5 mg tablets and 
telmisartan 80 mg/HCTZ 12.5 mg tablets, with BP-lowering 
effects maintained for long-term periods.37
Comparison with other 
combination tablets
To evaluate the effectiveness of fixed-dose combinations 
of ARBs with HCTZ, a multicenter, randomized, prospec-
tive, open-label, blinded-endpoint clinical study involving 
805 patients with mild-to-moderate hypertension was con-
ducted.38 The patients were randomly divided into 3 groups: 
telmisartan 40 mg/HCTZ 12.5 mg, losartan 50 mg plus 
HCTZ, or telmisartan 80 mg/HCTZ 12.5 mg. The primary 
endpoint of the mean reductions in the last 6 hours mean 
diastolic BP for the telmisartan 40 mg/HCTZ 12.5 mg 
and telmisartan 80 mg/HCTZ 12.5 mg group were signifi-
cantly higher: -2.0 mmHg (P = 0.0031) and -2.8 mmHg Integrated Blood Pressure Control 2010:3 78
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(P = 0.0003), respectively. The study demonstrated that 
during the last 6 hours of the 24-hour dosing interval, 
telmisartan 40 mg/HCTZ 12.5 mg produced a significantly 
reduced BP than losartan 50 mg/HCTZ 12.5 mg, which 
corresponds to the high-risk early-morning hours. (This study 
also showed further BP reduction by the administration of 
telmisartan 80 mg/HCTZ 12.5 mg). Therefore, telmisartan 
40 mg/HCTZ 12.5 mg is considered to inhibit the early 
morning BP elevation, and is thereby expected to prevent 
the onset of cardiovascular events.
The San Marino Observational Outlooking Trial on 
Hypertension study (SMOOTH ), a prospective, randomized, 
open-label, blinded-endpoint, multicenter trial, compared 
the BP-lowering effect between telmisartan 80 mg/HCTZ 
12.5 mg and valsartan 160 mg/HCTZ 12.5 mg for 840 
  overweight/obese hypertensive patients.39 After 10 weeks, the 
telmisartan 80 mg/HCTZ 12.5 mg group showed significantly 
greater reductions in BP than the valsartan 160 mg/HCTZ 
12.5 mg group in the last 6-hour mean ambulatory BP, 
and differences in favor of telmisartan/HCTZ: systolic BP 
3.0 mmHg, P = 0.0002; diastolic BP 1.6 mmHg, P = 0.0006) 
in the morning as well as during daytime and night-time 
  periods (P  0.003). Thus, the combination of telmisartan 
80 mg plus HCTZ 12.5 mg could be a more preferable 
treatment alternative than valsartan 160 mg plus HCTZ 
12.5 mg, especially for overweight/obese patients with 
hypertension.
Safety of telmisartan/HCTZ 
combination tablets
The adverse event rate with the telmisartan 40 mg/HCTZ 
12.5 mg combination tablet in the Japanese study was 11.2% 
(47/421)32: postural vertigo (12), dizziness (10), hyperuricemia 
(7), light-sensitive response (4), hypotension (3), hepatic 
dysfunction (3), and pollakiuria (2). In the Japanese phase 
III study, the patients who received telmisartan 40 mg/HCTZ 
12.5 mg combination tablet for 8 weeks showed no significant 
changes in serum K+, serum total cholesterol, and blood glu-
cose levels. Although elevation in the serum uric acid level 
was observed in the early phase, it declined gradually.36 In 
this situation, long-term use of telmisartan/HCTZ combina-
tion tablet least affects the metabolic pathway and does not 
clinically induce adverse effects.
Conclusions
Reduction in the number of drugs enhances the drug 
  compliance rate. For those who poorly responded and failed 
to achieve their BP goals with a single antihypertensive 
drug, the combination of ARB/HCTZ possibly offers 
additional benefits. The telmisartan/HCTZ combination 
tablet was demonstrated to have a strong and long-acting 
effect. Therefore, for the management of hypertension as 
recommended by the revised version of JSH 2009, using the 
telmisartan/HCTZ combination tablet has enormous promise 
in contemporary medical treatment.
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